Biomed-Lublin

Vaccines & plasma products · TB, immunology, bladder cancer

Overview

Maker of the BCG vaccine, Onko BCG bladder-cancer therapy and plasma-derived immunoglobulins — a rare Polish biologics manufacturer.

What they do

Biomed-Lublin is one of Poland's few full-scale biologics manufacturers, listed on the Warsaw Stock Exchange (GPW). Its portfolio spans the live BCG vaccine against tuberculosis, plasma-derived immunoglobulins and bacterial preparations, drawing on decades of fermentation and biological production know-how in Lublin.

Lead program & status

Its flagship oncology product is Onko BCG, an intravesical immunotherapy for non-invasive bladder cancer (carcinoma Ta, Tis, T1) based on the BCG Moreau Brazilian substrain, which is reportedly less reactogenic than other strains. The drug is marketed in Poland and exported to markets including Turkey, Hungary, Uruguay and the Middle East. As of 2024 the company was investing in a new commercial Onko BCG production line, a project valued at over PLN 48m and partly EU-grant funded, to expand capacity amid global BCG shortages.

Why it matters

Domestic manufacturing of BCG and plasma products gives Poland strategic supply security in vaccines and immunology. By scaling Onko BCG, Biomed-Lublin positions itself as a regional supplier in a market constrained by chronic shortages of bladder-cancer immunotherapy.

FAQ

Is Biomed-Lublin publicly traded?

Yes. Biomed-Lublin is listed on the Warsaw Stock Exchange (GPW).

What is Onko BCG used for?

Onko BCG is an intravesical BCG immunotherapy for non-invasive (superficial) bladder cancer, used as an alternative or supplement to chemotherapy.

What products does Biomed-Lublin make besides Onko BCG?

It manufactures the BCG tuberculosis vaccine, plasma-derived immunoglobulins and other biological preparations.

Company website / source ↗ Open the interactive map →